Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 191.01% | -193.54% | 16.24% | -6.78% | -20.65% |
| Total Depreciation and Amortization | -7.69% | 8.33% | 2.86% | 9.38% | 100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -350.15% | 401.46% | -49.25% | 93.40% | 11.72% |
| Change in Net Operating Assets | -119.09% | 6,327.84% | 110.36% | -191.27% | 8.23% |
| Cash from Operations | 27.23% | -5.57% | 13.03% | -18.89% | -27.13% |
| Capital Expenditure | -- | 94.59% | 41.27% | 14.86% | -11.28% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 48.61% | 573.05% | -127.69% | -44.19% | 0.42% |
| Cash from Investing | 48.68% | 553.17% | -129.49% | -44.59% | 0.29% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 636.87% | 47.82% | -90.45% | 16,465.52% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 364.26% | 47.82% | -90.45% | 16,465.52% | -- |
| Foreign Exchange rate Adjustments | -447.57% | -551.22% | -315.79% | -89.14% | -21.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 2,021.31% | 93.80% | -214.57% | 480.82% | -55.92% |